Testing a new antiviral medicine for hospitalized COVID-19 patients
Part of Infections, Lungs & breathing clinical trials.
This study tests an antiviral medicine called FS-1 (brand name Efesovir) in adults hospitalized with COVID-19 who have risk factors for severe illness. The goal is to see if the drug can help them recover faster or avoid more serious complications.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Adults aged 18 to 59 years
- Currently hospitalized for COVID-19, with symptoms for no more than 10 days
- Positive PCR test for COVID-19
- Not pregnant or breastfeeding, and willing to use reliable birth control during the trial
- No severe organ damage, certain blood or clotting problems, or need for a breathing tube
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an oral drug called SPI-1005 for people hospitalized with moderate COVID-19. The drug may help reduce inflammation and protect the lungs, and the study will compare it to a placebo (a pill with no active medicine) to see if it helps people recover.
This early-stage study tests COVID-19 treatments in people who have recently developed symptoms and who test positive for the virus. It aims to find safer, more effective options for preventing worsening disease, especially in higher-risk groups.
This trial looks at how well an antiviral works in the body when started early in people with COVID-19 symptoms. You may be able to join if you’re an otherwise healthy adult with confirmed infection and symptoms for less than 4 days.
This trial studies whether PF-07321332 (with ritonavir) helps children under 18 who have COVID-19 at home but are at high risk of severe illness. It looks at whether starting treatment early can reduce progression to worse disease.
This trial tests whether Codivir can help people hospitalized with moderate COVID-19 recover better than a placebo (inactive pill). It will compare outcomes while participants receive standard hospital care.
This study tests whether two antiviral medications, Paxlovid and Veklury (remdesivir), can reduce the risk of long-term heart and blood vessel problems after a COVID-19 infection. It is for adults recently hospitalized with COVID-19 who are not currently on oxygen therapy.
Hear when a new Covid19 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.